Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Total Non-Current Liabilities readings, the most recent being $97000.0 for Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 54.03% to $97000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $97000.0 through Mar 2026, down 54.03% year-over-year, with the annual reading at $128000.0 for FY2025, 45.99% down from the prior year.
  • Total Non-Current Liabilities hit $97000.0 in Q1 2026 for DiaMedica Therapeutics, down from $128000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $420000.0 in Q3 2022 and bottomed at $7000.0 in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $240823.5, with a median of $263000.0 recorded in 2024.
  • Peak annual rise in Total Non-Current Liabilities hit 13233.33% in 2022, while the deepest fall reached 72.73% in 2022.
  • DiaMedica Therapeutics' Total Non-Current Liabilities stood at $400000.0 in 2022, then dropped by 20.75% to $317000.0 in 2023, then fell by 25.24% to $237000.0 in 2024, then tumbled by 45.99% to $128000.0 in 2025, then decreased by 24.22% to $97000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Total Non-Current Liabilities are $97000.0 (Q1 2026), $128000.0 (Q4 2025), and $157000.0 (Q3 2025).